Trienomycin A derivatives inhibit the PI3K/AKT/mTOR pathway, inducing protective autophagy in pancreatic cancer cells. This approach shows promise for pancreatic ductal adenocarcinoma treatment, with current validation in cell lines and mouse models.
Trienomycin A and its derivatives represent a novel approach to treating pancreatic ductal adenocarcinoma (PDAC) by targeting the PI3K/AKT/mTOR signaling pathway. These compounds induce protective autophagy in cancer cells, potentially offering a new therapeutic strategy for this aggressive cancer type. The research indicates that by inhibiting this pathway, Trienomycin A can effectively reduce tumor growth, particularly when combined with autophagy inhibitors.
This research is currently at Technology Readiness Level 5, with successful validation in laboratory settings and ongoing in vivo studies to further establish efficacy and safety.
Northwest A&F University is a key national comprehensive university under China’s Ministry of Education, based in Yangling, Shaanxi. Co-located with the national Yangling Agricultural Hi‑Tech Demonstration Zone, it connects corporate partners to experimental farms, field stations, and demonstration bases across the region. The university’s Science and Technology Development Institute and Division of Science and Technology Extension streamline collaboration with local governments and leading enterprises, from contract research to field deployment and workforce training. Research is supported by competitive national funding, including the National Natural Science Foundation of China and programs of the Ministry of Science and Technology and the Ministry of Education. Technology transfer and extension services connect research outcomes with enterprises across the Yangling ecosystem.